Life Science Company News

AvevoRx Secures Limited Distribution Agreement for Alpha-1 Proteinase Inhibitor Zemaira®

Deal comes just months after AvevoRx announces an initial foray into the Alpha-1 market, adding to its already robust therapy offering for patients with the Alpha-1 deficiency

GREENSBORO, N.C., Dec. 5, 2023 /PRNewswire-PRWeb/ -- AvevoRx, a national, independent provider of specialty infusion pharmacy services, has secured a limited distribution deal for the Alpha-1 proteinase inhibitor (Human) Zemaira®. The treatment is the latest in AvevoRx's already robust therapy offerings for patients with an Alpha-1 deficiency, a hereditary and progressive condition that affects the lungs.

"The Alpha-1 community is in critical need of more treatment options, and being able to answer that charge while adding another drug and service offering in this space is very rewarding."

Ric Logsdon, program manager for AvevoRx, says the timing is right for both the company and the Alpha-1 community. "We are proud to now offer our growing number of patients the option of Zemaira as a therapy to help their Alpha-1 deficiency." He continued, "The Alpha-1 community is in critical need of more treatment options, and being able to answer that charge while adding another drug and service offering in this space is very rewarding. Our signature mix of speed, service, and simplicity will help ensure a truly custom treatment experience."

AvevoRx has rapidly expanded its geographic footprint in 2023 and has concurrently strengthened its clinical offerings to ensure as many patients as possible have access to the treatments and therapies they need. Founded in 2021 by a team of industry veterans, AvevoRx's management team has more than 100 years of combined expertise in Alpha-1 therapeutics and infusion services.

AvevoRx currently holds licenses in 26 states across the country. Visit AvevoRx.com for more information.

Zemaira is manufactured by CSL Behring LLC. For more information, visit Zemaira.com.

About AvevoRx

AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit www.AvevoRx.com or follow us on Instagram or LinkedIn.

Media Contact

Victoria Seremeta, AvevoRx, 1 5162861950, victoria@howleygroupllc.com, www.AvevoRx.com

Cision View original content to download multimedia:https://www.prweb.com/releases/avevorx-secures-limited-distribution-agreement-for-alpha-1-proteinase-inhibitor-zemaira-302002997.html

SOURCE AvevoRx

By: PR Newswire Association LLC. - 05 Dec 2023
Back to overview

Enhance your business development with Biotechgate